Castle's first disease target is atopic dermatitis, with the goal to develop a test that can predict future flare-ups of the disease.

NEW YORK – Visby Medical announced Tuesday that it has raised about $55 million in a recent financing round with the total potentially reaching $65 million.

NEW YORK — EDX Medical Group said on Monday that it has a signed a memorandum of understanding with UK-based healthcare group Spire Healthcare around diagnostic products and testing services.

NEW YORK – Scope Biosciences has secured €1 million ($1.2 million) in follow-on investment to scale its molecular diagnostics platform. The diagnostics developer said on Monday that the investment ...

The acquisition is intended to expand the French firm's presence in sequencing-based infectious disease testing.

The Birmingham, UK, firm hopes to develop a broader test menu with industry partners, using AI and machine-learning approaches.

The company uses artificial intelligence to detect metabolic patterns from urine samples that indicate prostate cancer.

The agency granted clearances for tests for cancer and precancer disorders, infectious respiratory diseases, and risk of sepsis and septic shock, among others.

The clinical lab giant is working with MD Anderson on an LDT for assessing cancer risk to drive uptake of recommended screenings and identify high-risk individuals for evaluation.

NEW YORK – Osteoporosis diagnostic firm Osteolabs announced Wednesday that it has entered into a strategic partnership with Swiss medical laboratory Labor Team to distribute Osteolabs' test for ...

NEW YORK — Gut microbiome health startup 32 Biosciences said on Tuesday that it has raised $6 million in private funding, which it said will support the development of its first products.

The protein biomarker-based test will be used to identify patients at high risk of cancer in order to prioritize them for conventional cancer screening methods.